Dilip Shanghvi
MD, Sun PharmaceuticalsBirth DetailsOctober 1, 1955 | Amreli, Gujarat, India
NationalityIndian
LeagueBusiness Leader
EducationB.Com Honours from University of Calcutta
Net Worth$7.55 billion (as of September 10, 2019)
Dilip Shanghvi's Assets:
Dilip Shanghvi's Journey so far ...
Before you go ...
Dilip Shanghvi's Journey so far ...
- Dilip Shantilal Shanghvi is a BCom graduate from the University of Calcutta. After his graduation, he helped his father in his pharma manufacturing facility for tablets
- He founded Sun Pharmaceutical Industries in 1983 with psychiatry medicines. In the same year, he set up a manufacturing facility for tablets.in Gujarat’s Vapi.
- He soon expanded the business and established a research centre to accelerate the development of drugs. Sun Pharma launched its IPO in 1994 which was oversubscribed 55 times
- Thanks to a series of acquisitions, Sun Pharma became India's largest pharmaceutical company and the world's fifth-largest speciality generics pharmaceutical company
- In 1996, Sun Pharma acquired Knoll Pharma's API plant in Ahmednagar and expanded its sales network across 24 countries. This was Sanghvi's first acquisition in India. Currently, Sun Pharma provides drugs and medicines to customers in over 150 countries
- In 1997, he helped Sun Pharma make its first international acquisition which was Caraco Pharmaceutical Laboratories, based out of Detroit. This acquisition gave Shanghvi access to the United States, which is the world's largest market for generic drugs
- Shanghvi guided Sun Pharma to acquire more than a dozen companies, the biggest among them being the 2010 purchase of Israel's Taro and Japan-based pharmaceutical giant Daiichi Sankyo owned Ranbaxy, which the company acquired in 2014
- Ranbaxy was Sun Pharma's biggest acquisition valued at around $4 billion, the deal led to a surge in the share price of the company and in 2015 Dilip Shanghvi overtook Mukesh Ambani as India's richest person
- In 2012, he stepped down as the Chairman of Sun Pharma for Israel Makov, the ex-CEO of Teva Pharmaceuticals
- A first-generation entrepreneur, Sanghvi helped Sun Pharma to launch products across cardiology, gastroenterology, neurology, ophthalmology and other segments which are still used today
- In 2018 the government of India appointed him to the central board committee of the Reserve Bank of India. He is also the Chairman of the Board of Governors at the Indian Institute of Technology, Bombay
Before you go ...
- Shanghvi borrowed Rs 10,000 from his father and started Sun Pharmaceuticals
- He loves South Indian food, and Mumbai's Madras Café and Matunga's Mysore Café are some of his favourite food joints
Last Updated: 15/02/2021
Dilip Shanghvi News
- Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acquisition ever by an Indian pharmaceutical company. The deal values Organon at $14 per share and gives Sun Pharma a major global expansion boost, including entry into the US women’s healthcare market and stronger presence across key international regions such as China, Europe, Korea, and Latin America.
- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai HQed company pips the consortium of EQT-Gruenthal. Sun will pay $4.5 billion for Organon’s equity and inherit $8.5 billion of its debt.
- Sun Pharma looks to outshine rival bids with $13 billion Organon offerSun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the Indian generics giant into a global leader in branded and innovative medicines. Sun Pharma is competing with other major players for the US company. The deal, if successful, would see Organon merge with Sun Pharma.
- Sun Pharma closes in on Organon buy, gets set for $12 billion binding bidSun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Following extensive due diligence, Sun is finalizing financing for the all-cash offer, aiming to bolster its position in branded and innovative drugs. This move signifies a strategic shift for the Indian pharma giant.
- Sun Pharma places non-binding offer for US-based Organon in its boldest global bet everSun Pharmaceutical Industries Ltd has submitted a non-binding offer to acquire US-based Organon for an all-cash deal, securing $10-14 billion in acquisition financing. This move marks Sun Pharma's boldest global bet, aiming to bolster its presence in women's health biopharma and biosimilars. The acquisition, if successful, would be the largest by an Indian pharmaceutical company.
- Sun Pharma's US innovative drug sales surpass generics for first timeSun Pharma is open to expanding its US manufacturing capabilities in response to the Trump administration's 100% tariff on medicines. The company is evaluating its current footprint and considering localization options, though the tariff's impact on its product portfolio remains uncertain. Sun Pharma also confirmed upcoming launches and R&D investments.
- Adaptability key for success in uncertain times: Sun Pharma's Dilip ShanghviDilip Shanghvi of Sun Pharma emphasized the importance of quick adaptation for business success. He spoke at an IFQM Symposium. Vivek Chaand Sehgal of Motherson Group sees challenges as growth opportunities. He noted unpreparedness leads to failure. Both leaders highlighted navigating the 'BANI' world. They believe adaptability is key for future success.
- Rs 40,000 crore dividend boom! How Ambani, Adani & India's top billionaires got richer in FY25India's top billionaires, including the Ambanis, Adanis, and Shiv Nadar, collectively amassed over ₹40,000 crore in dividends in FY25, showcasing India Inc's strong cash generation. Shiv Nadar led the pack with ₹9,902 crore, followed by Anil Agarwal's Vedanta at ₹9,591 crore. The surge in dividend income spanned across various sectors, highlighting generous payout policies.
- Kirti Ganorkar: Why the veteran insider is the right dose for Sun PharmaKirti Ganorkar, a long-time Sun Pharma veteran, will take over as Managing Director from September 1, succeeding founder Dilip Shanghvi, who remains Executive Chairman. This transition marks the culmination of Sun Pharma's succession plan, as Ganorkar steps into the role amidst a challenging global market.
- Sun Pharma appoints Kirti Ganorkar as MD; Dilip Shanghvi to continue as the Executive Chairman of the BoardSun Pharmaceutical Industries has appointed Kirti Ganorkar as Managing Director, succeeding Dilip Shanghvi, effective September 1. Shanghvi will continue as Executive Chairman, focusing on specialty portfolio and long-term strategy. Additionally, Richard Ascroft will succeed Abhay Gandhi as CEO – North America, reporting to Aalok Shanghvi, who takes on additional responsibility for the North America business.
- Sun Pharma lines up $100 mn to commercialise niche products this fiscalSun Pharmaceutical Industries plans a USD 100 million investment to commercialize innovative products this fiscal year, focusing on its specialty business. The company will launch Unloxcyt and Leqselvi, while seeking a partner for MM-II development. Sun Pharma anticipates mid-to-high single-digit consolidated topline growth for FY26 and expects R&D spending to be 6-8% of sales.
- Sun Pharma aims to launch anti-obesity and type 2 diabetes drug Utreglutide in five years: Dilip ShanghviSun Pharmaceutical, India's largest drugmaker by revenue, plans to launch its experimental anti-obesity and type 2 diabetes drug Utreglutide in the next four to five years, said Managing Director Dilip Shanghvi. The drug is a GLP-1 receptor agonist and has shown promising results in early trials. Sun Pharma is focusing on launching the drug in India and global markets.
- US tariffs won't hurt Indian pharma and steel exports: TycoonsIndian pharmaceutical and steel sectors show resilience against proposed US trade tariffs. Sun Pharma's Shanghvi indicates limited impact on the pharma industry due to critical healthcare needs. Meanwhile, Jindal Steel's Jindal reveals India's strong domestic steel consumption may mitigate the effects of the 25% tariffs on imported steel.
- Sun Pharma promoter Vibha Shanghvi buys two luxury apartments in Mumbai’s Worli for Rs 130 croreVibha Shanghvi, wife of Sun Pharmaceuticals Founder Dilip Shanghvi, purchased two luxury apartments in Mumbai's Worli for Rs 130 crore. The transactions involved high-value properties with exclusive parking spaces, highlighting the surge in premium residential property sales in Mumbai's upscale localities.
- Meet the woman who plays a key role in Rs 4.35 lakh crore pharma empireVidhi Shanghvi, daughter of India's richest healthcare billionaire Dilip Shanghvi, plays a key role in Sun Pharmaceutical Industries Ltd. As Vice President, she shapes the company's strategic direction. Beyond her corporate role, she champions mental health through her non-profit, Mann Talks.
- Govt slaps fine on Sun Pharma officials over related party transactionsSun Pharmaceutical Industries Ltd has been penalized by the Ministry of Corporate Affairs for non-disclosure and failure to obtain necessary board and shareholder approvals for certain related party transactions in the past. The penalties apply to certain past and present directors and officials. The issues relate to transactions from financial years 2014-15 to 2018-19.
- Govt slaps fine on Sun Pharma officials over related party transactionsSun Pharmaceutical Industries Ltd has been penalized by the Ministry of Corporate Affairs for non-disclosure and failure to obtain necessary board and shareholder approvals for certain related party transactions in the past. The penalties apply to certain past and present directors and officials. The issues relate to transactions from financial years 2014-15 to 2018-19.
- Mukesh Ambani's $108 bn net worth places him on top of Forbes 2024 rich list as India's collective wealth surpasses $1 tnMukesh Ambani, chairman of Reliance Industries, leads the 2024 Forbes list of India's richest, with a net worth of $119.5 billion. The combined wealth of India's top 100 tycoons has surged to over $1.1 trillion, marking a 40% increase from last year. The wealth growth is attributed to a booming stock market, with over 80% of individuals on the list becoming wealthier, driven by strong investor interest in IPOs and mutual funds.
- Top 10 billionaires added Rs 13.39 lakh crore to net worth in 1 yearBillionaires Gautam Adani and Mukesh Ambani, the top two wealthiest Indians on the 2024 Hurun India Rich List, added Rs 12.54 lakh crore, boosting their total wealth to Rs 35.57 lakh crore.
- Adanis, Ambanis or Birlas: Who are the top 10 richest Indians?Gautam Adani tops the 2024 Hurun India Rich List with a 95% wealth increase, followed by Mukesh Ambani and Shiv Nadar. The list shows India’s rising billionaire count.
- Sun Pharma expects high single-digit top line growth in current fiscalSun Pharmaceutical Industries expects high single-digit top line growth in FY24 with total revenue at Rs 48,497 crore, led by Managing Director Dilip Shanghvi. The firm anticipates similar growth in FY25 with investments in product launches and R&D activities.
- Taro shareholders approve merger with Sun PharmaThe combined entity will enable the company to better serve the needs of patients, healthcare professionals and customers around the world, he added. Upon completion of the merger, currently expected to close in around 35 days, Taro will become a privately held company, wholly-owned by Sun Pharma and soon after its shares will be de-listed from the NYSE.
- Indian pharmaceutical industry set for major transformation: Dilip ShanghviAt an annual meeting of the USA-India Chamber of Commerce in Boston, Shanghvi told a gathering of leading multinational drug makers about the "clear positive improvements" that are taking place in India. Sun Pharma itself has built a pipeline of over 10 specialty and innovative drugs in the US. It's done this through acquisitions of late-stage drugs in clinical trials and building commercial teams around them. For Indian companies that have grown by making copies of innovative drugs, gaining presence in innovative drugs is considered tough as this segment is dominated by giant corporations such as Pfizer, Novartis, Roche, Eli Lilly and Bristol Myers Squibb.
- Mumbai beats Beijing to emerge as the new billionaire hub of Asia, Hurun Research's list showsMumbai has become Asia's leading billionaire hub, surpassing Beijing for the first time, according to Hurun Research's 2024 Global Rich List. The financial capital of India now has 92 billionaires, edging past Beijing's 91. This places Mumbai third globally in terms of billionaires, with New York leading with 119 and London with 97.
- Tata Sons, TVS Motor, 5 other cos launch Indian Foundation for Quality ManagementIndian Foundation for Quality Management, led by prominent industry figures, strives to enhance quality and innovation in Indian businesses, aiming to compete globally and unlock their true potential.
- Interim Budget 2024: Laying bedrock for development, growthThe interim budget exemplifies the government's dedication to Viksit Bharat. It focuses on fortifying the economy, boosting infrastructure, and promoting green growth through bio-manufacturing. The budget also expands universal health coverage and introduces the cervical cancer vaccination program.
- Sun Pharma aims to spend 7-8 pc of sales on R&D this fiscalThe Mumbai-based drug major spent about Rs 2,400 crore on R&D in 2022-23, which accounted for about 5.5 per cent of the sales as it continued to invest product pipeline for both global generics and specialty businesses.
- 2023 M3M Hurun Global Rich List: Indian billionaires richest against their global peers in these 5 sectorsIndia is also home to the richest aviation billionaires, with a wealth of $3.6 billion and $3.3 billion, Rakesh Gangwal and Rahul Bhatia and family of Indigo Airlines are the wealthiest aviation billionaires.
- CFO on Suzlon Energy rights issue, debt repayment and order book“The Rs 3,200-crore debt that is seen on 30th June 2022 balance sheet, would be reduced by Rs 900 crore once the entire rights issue call money has been made available to the company and that is in addition to the scheduled repayments which are ongoing from the operational cash flows of the company. As we approach the March 2023 balance sheet, it will be a much healthier, more linear balance sheet."
- Sun Pharma’s Shanghvi to participate in Suzlon Energy’s rights issueSanghvi holds a 4.2 per cent stake in the wind turbine maker.
- Sun Pharma, other drug cos say innovative products to contribute substantially in futureSun Pharma, India's largest drug maker, said it expects its innovative products to garner $1.5 billion in sales in the next 3-4 years.
- Sun Pharma eyes acquisitions in US, Europe and emerging marketsWith a market share of 8.1% as per market research firm AIOCD-AWACS in September 2021, Sun Pharma has the highest share in the domestic pharmaceutical market.
- SPARC raises over Rs 1,110 cr; issues warrants to promoter Dilip Shanghvi, othersThe issue price includes the warrant subscription price (Rs. 44.50 per warrant) and the warrant exercise price (Rs. 133.50 per warrant).
- No plans to get into vaccine production as it requires separate manufacturing infra: Sun Pharma"I think our preliminary assessment indicates that vaccines will require a dedicated manufacturing facility and it cannot be produced in a facility where we are making multiple other products," Sun Pharmaceutical Industries Managing Director Dilip Shanghvi said in a call with analysts.
- Dilip Shanghvi resigns as MD of SPARCIt further stated that the board, on the recommendation of Nomination and Remuneration Committee, has appointed Anil Raghavan as chief executive officer (CEO) of the company with immediate effect for a term of five years till May 24, 2026.
- Adani adds more billions to his wealth than 19 peers, closing in on AmbaniAmong the 20 Indian billionaires on Bloomberg Billionaire Index, Adani's fortunes have risen by $35.2 billion in 2021 so far, compared with a $24.5 billion addition in the combined wealth of 19 other Indian billionaires.
- Sun Pharma Advanced issues warrants worth Rs 1,200 cr to promoter, marquee investors like JhujhunwalaThe company will issue 6.74 lakh warrants that can be converted to one equity share of the company over the next 18 months, a stock exchange filing by the company showed.
- Analysis: What does the Sebi settlement mean for Sun Pharma?However, this is not the first time that Sun Pharma and its promoter have been involved in a Sebi settlement. In 2017, Sun Pharma, its founder Dilip Shanghvi and nine others had settled an alleged insider trading violations with Sebi.
- Sun Pharma, officials including Dilip Shanghvi settle case of alleged mkt norms violation with SebiThe firm's whole-time directors - Sudhir V Valia and Sailesh T Desai - paid Rs 37.41 lakh each, and Kalyanasundaram Subramanian had to remit a settlement amount of Rs 36.97 lakh.
- Aditya Medisales case: Sebi accepts settlement pleas of Sun Pharma, promotersSebi had initiated a probe against Sun Pharma, its managing director Dilip Shanghvi and its directors on the basis of two whistleblower complaints.
- Apple cofounder Steve Wozniak to headline ET Innovation AwardsWozniak will also engage with industry chieftains including Sanjiv Bajaj, chairman and MD, Bajaj Finserv; Gopal Vittal, MD and CEO, Bharti Airtel, India and South Asia; and Sindhu Gangadharan, senior vice president and MD, SAP Labs India.
- Will continue to focus on growing businesses faster than market: Sun PharmaDrug major Sun Pharma will remain focussed on growing its businesses faster than the market in which it operates, the company said in its Annual Report 2019-20.
- Aim to gain market share, protect supply chain, preserve cash amid COVID-19 uncertainties: Sun Pharma"Our endeavour will be to gain market share in each of our business by doing better. Despite the near-term uncertainties related to COVID-19, we hope to be able to do better consistently," Sun Pharmaceutical Industries MD Dilip Shanghvi said in an analyst call.
- Suzlon board okays debt rejig plan to convert loans to equityThe wind turbine maker also passed an enabling resolution for conversion of loan and debentures into equity
- Sun Pharma eyes China, Japan marketsShanghai now plans to steer the company into the specialty business (novel, innovative drugs), and towards expanding markets like China and Japan for growth, both through acquisitions and partnerships.
- Wind turbine maker Suzlon Energy plans debt rejig after stake sale failsSuzlon defaulted on loan repayments earlier this year and its loans were categorised as NPAs.
- India's 10 richest people: How much they lost and gained in the past one yearDid you know that Mukesh Ambani's networth is equal to 2.1% of India's GDP? And even after losing 10% of his networth, Lakshmi Mittal is still worth $12.4 billion? Read on to see how much India's 10 richest men gained and lost in the past year.
- Investors can wait for Sun to shine in Japan and ChinaHistorically, strategy formulation and execution has been one of the key strengths of Sun Pharma.
- Mukesh Ambani richest Indian with net worth of Rs 3,80,700 crore: ReportMukesh Ambani has topped the list of richest Indians for the eighth consecutive year.
- Suzlon Energy bankers stare at haircut on loans in new debt recast planTwo international companies had shown interest at different stages, but both have subsequently pulled out.
- Sun Pharma to make upfront payment worth Rs 2.40 bn to CSIR-IICT Hyderabad for new drug compoundsThis collaboration with CSIR-IICT for developing new drugs is part of our broader strategy for enhancing our global specialty pipeline.
- Is Sun Pharma on the road to recovery?Sun Pharma’s consolidated net sales grew 16 per cent on back of favourable growth.
- At Rs 58.8 cr, Murali of Divi's Lab highest paid Indian pharma executiveThe percentage increase in the median remuneration for the staff of the firm for FY19 was 3.96 per cent.
- FM Sitharaman assures industry of ‘Quick Action’Among other things, industry leaders have sought tax rationalisation and a package for NBFCs.
- Sun Pharma eyes 'low-to-mid teens' growth in revenues for FY20Sun is targeting key ailments like psoriasis to ramp up its global specialty business.
- Suzlon stares at FCCB default, tells bondholders to hold onResolution hinges on banks’ approval of settlement plan, Brookfield deal.
- Suzlon may default on Rs 1.2K crore FCCBs due JulyThe Pune-based company is facing the liquidity crisis as it has no resolution plan in place.
- Firm on pharma, Dilip Shanghvi surrenders NBFC licenceRBI puts on hold Shanghvi Finance's request for core investment company licence.
- Some of these PSUs could be money spinners this year: Deven ChokseySome of the PSUs which got completely derated, now have the prospect of getting rerated, says Choksey.
- What to watch out for in Sun Pharma’s Q4 resultsThe drug major is expected to post a 12.3 per cent increase in net sales to Rs 7,537 crore.
- Sudhir Vaila looks to raise up to Rs 500 croreDeutsche Bank along with another foreign lender may extend the three-year credit expected to come from the lender’s overseas branch, two people familiar with the matter, said.
- Indian Pharma’s incentives to do business in US on steady declineAlthough revenues from the US have risen, margins have taken a hit
- China's war on healthcare costs lures India's biggest drugmakerShanghvi believes market watchers are underestimating the potential in China for India’s largest drugmaker.
- Irda rejects Watsa's plan to buy Sudhir Valia’s ITI ReinsuranceRegulator says company’s licence stipulates 5-year lock-in during which its shares can’t be sold.
- Shareholders not disadvantaged in transactions with Aditya Medisales: Sun PharmaShanghvi was responding to the concern raised by some investors whether Aditya Medisales has benefited in the past at the cost of Sun Pharma's minority shareholders.
- Got 2 queries from Sebi: Sun PharmaSun Pharma’s shares have been volatile in the last two months.
- Sun to overhaul business practices to allay concernsSun Pharma's domestic formulations biz would be transitioned from Aditya Medisales to a wholly owned arm.
- Sun Pharma not to regain lost reputation in a hurry: Shriram Subramanian, InGovern Research“Sun paid 6,00,000 euros as commissions to Aalok Shanghvi in 2011/12 and nobody raised a question.”
- There is no diversion of funds at all: Sudhir Valia, director, Sun PharmaSudhir Valia, brother-in-law of Sun Pharma promoter Dilip Shanghvi, in a telephonic chat with Divya Rajagopal, discusses the issues of Aditya Medisales, raising money through debt papers for Suraksha Realty by involving Shanghvi Finance.
- Sun promoters pledged firm's shares for SurakshaShanghvi's brother-in-law and realty co owner Valia denies drugmaker stood guarantee for fundraising.
- Sun Pharma dives 12% on buzz over fresh whistleblower complaint; here’s what analysts saySebi last month confirmed reports that it had received a whistleblower complaint against Sun.
- Sun Pharma promoters take a hit on personal investmentsSome of their biggest personal investments have been in power and real estate, and both sectors and their holdings have taken a beating, according to publicly available data.
- Investors irked by lack of disclosures at Sun PharmaThe lack of disclosures around non-related party transactions to the tune of Rs 2,200 crore has become a sore spot for investors, who are questioning the nature — and beneficiaries — of these loans.
- Sun Pharma open to evaluating past decisions: Dilip ShanghviA WhatsApp forward leaked details of a report containing allegations of corporate governance improprieties
- Sun Pharma profits drag on possible anti-trust settlementSun Pharma posted a total income of Rs 6846 crore, a 4 per cent growth.
- Sun pharma invests 120 crore in Assam to set up production lineAccording to statement from Assam government the company has already invested Rs 700 crore in this manufacturing facility in the state and another Rs 200 crore is going to be invested.
- Sun Pharma shares rally after USFDA reclassifies Halol Unit as 'No Action Initiated'USFDA no action initiated status means clearance for the unit.
- Sun Pharma expects normalisation of India business in FY'19Sun Pharma MD Dilip Shanghvi said the government's enforced price cuts and policy changes are potential risk factors for the business.
- Reliance's Mukesh Ambani earned Rs 300 crore per day over last one yearAmbani holds the top position for a 7th year on over 45% rise in shares of Reliance.
- Sun marches ahead with its specialty pipeline, announces European approval for TildraIn the last two months Sun Pharma has received approval for four drugs from its pipeline after a dry spell of nearly 2 years.
- Will Sun Pharma get its mojo back on Dalal Street?Encouraging Q1 numbers and clearance for Halol facility by USFDA boost investor confidence.
- USFDA clears Sun Pharma’s Halol plant, two years after it went under import banThe USFDA’s Establishment Inspection Report (EIR) comes days after the company received Voluntary Action Indicated (VAI) that indicated that clearance for the plant wasn’t too far away.
- Sun Pharma rises with R&D and bets on specialty drugsSun Pharma- India's largest drug maker - is vying for its share in the US$9 billion market through a drug, Ilumya, that treats moderate-to-severe psoriasis.
- Ambani, Adani and three other billionaires have just lost $15 billionWhen Modi government came to power in 2014, Adani was one man projected to benefit the most.
- Jaypee Infra lenders reject Lakshadweep’s proposalETon May 3 reported that the committee was set to reject the offer from Lakshadweep, a venture promoted by some relatives of pharma billionaire Dilip Shanghvi.
- Can pharma learn from auto? Of course!The drug industry is facing threats from unexpected rivals such as Google and Samsung, while the auto sector is grappling with new-age nemeses like Google and Tesla.
- Is Sun Pharma's Halol site close to a rebound?About 40% of the US revenues of Sun Pharmaceutical Industries, India's most valuable pharmaceutical company, is linked to its Halol site.
- Future belongs to those who innovate: Benjamin Netanyahu to India Inc"It is very, very crucial today for you and your Israeli counterparts to meet up, because the future belongs to those who innovate," Netanyahu said.
- Shalom Mumbai: Benjamin Netanyahu meets business leaders, lauds tiesBusiness leaders who were present at the breakfast included Ajay Piramal, Rahul Bajaj, Adi Godrej, Harsh Goenka, Anand Mahindra, Dilip Shanghvi, Ashok Hinduja, Atul Punj and Chanda Kochhar.
- ETMarkets After Hours: RCom rally on; DLF slips post GIC dealShares of Reliance Communications extended their rally into the second straight session.
- Wockhardt chairman Habil Khorakiwala’s double celebration included a 10-course meal, & the crème de la crème of MumbaiKhorakiwala brought in his 75th birthday and his company’s golden jubilee with a lavish party.
- Speciality segment to be a key growth driver for Sun PharmaWhile these investments currently do not generate commensurate revenues streams, they will augur well for the company in the long term as more speciality products get commercialised.
- Credit Suisse upgrades Sun Pharma; shares surgeCredit Suisse raised target price of Sun Pharma to Rs 595 from Rs 490 earlier.
- Sun Pharma sees single-digit decline in revenues for FY18The company's consolidated R&D investments for FY18 will be about 9-10 per cent of revenues.
- Giving a boost to cancer care one drop at a timeYes Bank inaugurated its water purification system and digital banking solutions in Nagpur last week.
- Billionaire Dilip Shanghvi offers mea culpa after Sun Pharma lossSun was tipped into a loss this quarter after it agreed to pay plaintiffs including Canadian rival Apotex to settle a lawsuit over sleep-disorder drug.
- Pharma woes wipe out nearly Rs 91,000 crore from wealth of once-richest IndianOnce richest Indian, Sun Pharma's Dilip Shanghvi slipped to No. 6 with his fortune dropping $14.1 billion from its peak of about two years ago.
- $14 billion loss in 2 years for Indian tycoon shows pharma in real bad shapeThe founder of Sun Pharma has seen his net worth fall to $11.1 billion on Bloomberg Index.
- Dilip Shanghvi's swift slide on the Indian billionaire listShanghvi is the third richest in the global healthcare industry after Ernesto Bertarelli.
- What went wrong for Sun Pharma: A tragedy in 4 partsOne of the overhangs on the Sun Pharma stock is the uncertainty over the DoJ enquiry.
Trending In Profiles
Mukesh AmbaniRatan TataAnand MahindraSundar PichaiGautam AdaniElon MuskAnil AmbaniYogi AdityanathRakesh JhunjhunwalaRadhakishan DamaniNarendra ModiByju RaveendranNitin GadkariSmriti IraniKiran Mazumdar ShawJeff BezosNandan NilekaniJack DorseyWarren BuffettBill Gates
DisclaimerThe content of this page has been aggregated from multiple websites. Some information can change over the passage of time.